Lyell Immunopharma, Inc. (LYEL)
25.26
+0.96
(+3.95%)
USD |
NASDAQ |
Jan 09, 13:35
Lyell Immunopharma Research and Development Expense (Annual): 152.28M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Insmed, Inc. | 598.37M |
| Nektar Therapeutics | 119.64M |
| GT Biopharma, Inc. | 5.798M |
| Ionis Pharmaceuticals, Inc. | 901.53M |
| Regeneron Pharmaceuticals, Inc. | 4.624B |